AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...

AbbVie, Inc. (ABBV) is currently at $165.64, down $4.00 or 2.36% --Would be lowest close since July 3, 2024, when it closed at $163.84 --Currently down eight consecutive days; down 17.87% over this ...

Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously announced initial public offering in the United States of 970,000 units, at a price of US$4 ...

Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.

Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for ...

Liberty Media Corp. Series C Liberty Formula One-1.27% $26.55B Liberty Media Corp. Series A Liberty Formula One-1.52% $26.55B ...